COMPARATIVE CARDIOVASCULAR SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AMONG INDIVIDUALS WITH OSTEOARTHRITIS; FINDINGS FROM PROVINCIAL PRESCRIPTION CLAIM RECORDS IN BRITISH COLUMBIA, CANADA

Mohammad Atiquzzaman1,2, Ehsan Karim1,2, Hubert Wong3, Jacek Kopiec2,3, Mary De Vera2,3, Aslam Aris2,3.

1University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, Canada; 2Arthritis Research Canada, Richmond, Canada; 3University of British Columbia, School of population and public health, Vancouver, Canada

COMPARATIVE CARDIOVASCULAR SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AMONG INDIVIDUALS WITH OSTEOARTHRITIS; FINDINGS FROM PROVINCIAL PRESCRIPTION CLAIM RECORDS IN BRITISH COLUMBIA, CANADA

Mohammad Atiquzzaman1,2, Ehsan Karim1,2, Hubert Wong3, Jacek Kopiec2,3, Mary De Vera2,3, Aslam Aris2,3.

1University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, Canada; 2Arthritis Research Canada, Richmond, Canada; 3University of British Columbia, School of population and public health, Vancouver, Canada

Background: Osteoarthritis (OA) has been reported as an independent risk factor for cardiovascular diseases (CVD) (1). Furthermore, mediating role of NSAIDs in the observed OA-CVD association has also been noted (2). Thus, a substantial proportion of the total risk of CVD among OA patients compared to non-OA controls was attributable to NSAID use (2). This is particularly worrisome as there is no cure for OA and NSAIDs are the mainstay of treatment in controlling the primary symptoms of pain and inflammation among OA patients. However, only a handful of observational studies evaluated the risk of a specific NSAID use in OA patients for a specific CVD event such as myocardial infarction (MI) (3). The overall cardiovascular safety of NSAIDs used in treating OA in the real-world therefore remains unknown.

Objective: To evaluate the comparative safety of various NSAIDs against CVD when treating patients with OA.

Methods: We used linked health administrative data (HAD) of a previously as well as population-based cohort of 720,055 British Columbians from Canada. We identified individuals with OA who received at least one NSAID prescription from January 1996 to December 2013. Eligible study subjects were at least 20 years old, did not have CVD and had not received an NSAID prescription within the last 90 days from their OA diagnosis date. We defined composite CVD outcome from hospital discharge abstract database, payment information file of Medical Services Plan and vital statistics deaths data file using ICD-9 or ICD-10 codes. We created an NSAID exposure variable in a time-dependent fashion in which individuals were considered at risk for the duration of NSAID prescriptions. We used time-dependent Cox regression analysis to estimate CVD risk associated with NSAID use overall as well as four unique groups of NSAIDs, i.e., coxibs, naproxen, ibuprofen and other conventional NSAIDs.

Results: Our cohort included 3,806 OA individuals. There were 1,147 CVD events. After adjusting for age, sex, SES, COPD, diabetes, hypertension, hyperlipidemia, peptic ulcer disease and Romano comorbidity score, the hazard ratio (HR) and 95% confidence interval (CI) from the time-dependent Cox regression model was 1.48 (1.27, 1.73). When exposure to different groups of NSAID was compared with unexposed person-time, CVD risk were similar among coxibs and naproxen followed by other conventional NSAIDs and ibuprofen, adjusted HR (95% CI) were 1.58 (1.24, 2.00), 1.58 (1.11, 2.24), 1.39 (1.10, 1.75) and 1.36 (0.75, 2.47), respectively.

Conclusion: Our study is the first retrospective cohort study using BC HAD that looked at the overall CVD risk of NSAID use in treating OA in a real-world setting. After modelling exposure to NSAIDs as time-dependent, we found that exposure to NSAIDs substantially increased overall CVD risk compared to non-exposed periods. We also found that coxibs and naproxen may increase CVD risk more than conventional NSAIDs. Further research is needed to determine the clinical outcomes data in a real-world setting. After modelling exposure to NSAIDs as time-depend-ent, we found that exposure to NSAIDs substantially increased overall CVD risk compared to non-exposed periods. We also found that coxibs and naproxen may increase CVD risk more than conventional NSAIDs.

REFERENCES


Disclosure of Interests: Mohammad Atiquzzaman: None declared, Ehsan Karim: None declared, Hubert Wong: None declared, Jacek Kopiec: None declared, Mary De Vera: None declared, Aslam Aris Grant/research support from: Not related to the research presented in this abstract, Consultant for: AbbVie, Actelion, Amgen, BMS Corbus, NIH, Myriad.

Disclosure of Interests: Mohammad Atiquzzaman: None declared, Ehsan Karim: None declared, Hubert Wong: None declared, Jacek Kopiec: None declared, Mary De Vera: None declared, Aslam Aris Grant/research support from: Not related to the research presented in this abstract, Consultant for: AbbVie, Actelion, Amgen, BMS Corbus, NIH, Myriad.

SA06001 MORTALITY RATE IN PATIENTS TREATED WITH BIOLOGICS: DATA FROM THE ROMANIAN REGISTRY OF RHEUMATIC DISEASES

Catalin Codreanu1, Corina Mogosan2, Denisca Predeteanu3, Simona Rednic4, Magda Parvu5, Elena Rezus6, Ruxandra Ionescu7, Romanian Registry of Rheumatic Diseases. 1Clinical Center of Rheumatic Diseases “Dr. Ion Stoia”, Rheumatology, Bucharest, Romania; 2Clinical Center of Rheumatic Diseases “Dr. Ion Stoia”, Rheumatology, Bucharest, Romania; 3Stanta Maria” Hospital, Rheumatology, Bucharest, Romania; 4County Emergency Hospital, Rheumatology, Cluj-Napoca, Romania; 5Clinical Hospital “Colentina”, Rheumatology, Bucharest, Romania; 6Clinical Rehabilitation Hospital, Rheumatology, Iasi, Romania; 7Stanta Maria” Hospital, Rheumatology, Bucharest, Romania

Background: Rheumatoid arthritis (RA) is associated with increased mortality, with longitudinal studies averaging a standardized mortality ratio of